• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Infect Dis . Incorporating real-time influenza detection into the test-negative design for estimating influenza vaccine effectiveness: The real

tetano

Editor, Senior Moderator
Clin Infect Dis


. 2020 Sep 25;ciaa1453.
doi: 10.1093/cid/ciaa1453. Online ahead of print.
Incorporating real-time influenza detection into the test-negative design for estimating influenza vaccine effectiveness: The real-time test-negative design (rtTND)


Leora R Feldstein[SUP] 1 [/SUP], Wesley H Self[SUP] 2 [/SUP], Jill M Ferdinands[SUP] 1 [/SUP], Adrienne G Randolph[SUP] 3 4 [/SUP], Michael Aboodi[SUP] 5 [/SUP], Adrienne H Baughman[SUP] 2 [/SUP], Samuel M Brown[SUP] 6 [/SUP], Matthew C Exline[SUP] 7 [/SUP], D Clark Files[SUP] 8 [/SUP], Kevin Gibbs[SUP] 8 [/SUP], Adit A Ginde[SUP] 9 [/SUP], Michelle N Gong[SUP] 10 [/SUP], Carlos G Grijalva[SUP] 2 [/SUP], Natasha Halasa[SUP] 11 [/SUP], Akram Khan[SUP] 12 [/SUP], Christopher J Lindsell[SUP] 2 [/SUP], Margaret Newhams[SUP] 3 4 [/SUP], Ithan D Peltan[SUP] 6 [/SUP], Matthew E Prekker[SUP] 13 [/SUP], Todd W Rice[SUP] 2 [/SUP], Nathan I Shapiro[SUP] 14 [/SUP], Jay Steingrub[SUP] 15 [/SUP], H Keipp Talbot[SUP] 2 [/SUP], M Elizabeth Halloran[SUP] 16 17 [/SUP], Manish Patel[SUP] 1 [/SUP], Influenza Vaccine Effectiveness in the Critically Ill (IVY) Investigators and the Pediatric Intensive Care Influenza Vaccine Effectiveness (PICFLU-VE) Investigators



Affiliations

Abstract

With rapid and accurate molecular influenza testing now widely available in clinical settings, influenza vaccine effectiveness (VE) studies can prospectively select participants for enrollment based on real-time results rather than enrolling all eligible patients regardless of influenza status, as in the traditional test-negative design (TND). Thus, we explore advantages and disadvantages of modifying the TND for estimating VE by using real-time, clinically available viral testing results paired with acute respiratory infection eligibility criteria for identifying influenza cases and test-negative controls prior to enrollment. This modification, which we have called the real-time test-negative design (rtTND), has the potential to improve influenza VE studies by optimizing the case-to-test-negative control ratio, more accurately classifying influenza status, improving study efficiency, reducing study cost, and increasing study power to adequately estimate VE. Important considerations for limiting biases in the rtTND include the need for comprehensive clinical influenza testing at study sites and accurate influenza tests.

Keywords: Influenza; clinical testing; real-time test-negative design; test-negative design; vaccine effectiveness.
 
Back
Top Bottom